Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ironwood Pharmaceuticals, Inc.    IRWD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector news 
Most relevant news about IRONWOOD PHARMACEUTICALS,
11/13 IRONWOOD PHARMACEUTICALS : Highlights ZURAMPIC® (lesinurad) Phase III Extension ..
11/10 IRONWOOD PHARMACEUTICALS : to Present at Stifel 2016 Healthcare Conference
11/03 IRONWOOD PHARMACEUTICALS : reports 3Q loss
11/03 IRONWOOD PHARMACEUTICALS : Provides Third Quarter 2016 Investor Update
11/01 IRONWOOD PHARMACEUTICALS : to Present at Credit Suisse 25th Annual Healthcare Co..
10/25 IRONWOOD PHARMACEUTICALS : Highlights Breadth of Gout Research with Presentation..
10/20 IRONWOOD PHARMACEUTICALS : to Host Third Quarter 2016 Investor Update Call
10/13 IRONWOOD PHARMACEUTICALS : CAMBRIDGE Cyclist dies in crash with 18-wheeler Accid..
10/13 IRONWOOD PHARMACEUTICALS : Accident claims life of Lexington man
10/03 IRONWOOD PHARMACEUTICALS : Nine in Ten Physicians Agree Target Goal for Gout Is ..
10/03 IRONWOOD PHARMACEUTICALS : Announces U.S. Availability of ZURAMPIC® (lesinurad) ..
09/26 IRONWOOD PHARMACEUTICALS : Closes $150 Million Debt Refinancing
09/07 IRONWOOD PHARMACEUTICALS : to Present at Morgan Stanley Global Healthcare Confer..
09/01 IRONWOOD PHARMACEUTICALS : to Present at Wells Fargo 2016 Healthcare Conference
08/05 IRONWOOD PHARMACEUTICALS : reports 2Q loss
More most relevant news
All news about IRONWOOD PHARMACEUTICALS,
11/22 IRONWOOD PHARMACEUTICALS : to Present at Stifel 2016 Healthcare Conference
11/14 IRONWOOD PHARMACEUTICALS : Assigned Patent
11/13 IRONWOOD PHARMACEUTICALS : Highlights ZURAMPIC® (lesinurad) Phase III Extension ..
11/10 IRONWOOD PHARMACEUTICALS : to Present at Stifel 2016 Healthcare Conference
11/10 IRONWOOD PHARMACEUTICALS : to Present at Credit Suisse 25th Annual Healthcare Co..
11/07 IRONWOOD PHARMACEUTICALS : Management's Discussion and Analysis of Financial Con..
11/04 IRONWOOD PHARMACEUTICALS : Assigned Patent
11/03 IRONWOOD PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fi..
11/03 IRONWOOD PHARMACEUTICALS : reports 3Q loss
11/03 IRONWOOD PHARMACEUTICALS : Provides Third Quarter 2016 Investor Update
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
11/26 Johnson & Johnson approaches Actelion about takeover deal
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
11/28 A Company On The Verge Of Profiting
11/03 Ironwood Pharmaceuticals' (IRWD) CEO Peter Hecht on Q3 2016 Results - Earning..
11/03 Ironwood Pharmaceuticals, Inc. 2016 Q3 - Results - Earnings Call Slides
11/03 Ironwood Pharmaceuticals beats by $0.06, beats on revenue
11/02 Notable earnings before Thursday?s open
10/05 Synergy Pharmaceuticals Getting Closer To 'Go Time'


Advertisement
Financials ($)
Sales 2016 256 M
EBIT 2016 -71,9 M
Net income 2016 -107 M
Debt 2016 153 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 9,46x
EV / Sales 2017 7,14x
Capitalization 2 268 M
More Financials
Chart IRONWOOD PHARMACEUTICALS,
Duration : Period :
Ironwood Pharmaceuticals,  Technical Analysis Chart | IRWD | US46333X1081 | 4-Traders
Full-screen chart
Technical analysis trends IRONWOOD PHARMACE...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 15,4 $
Spread / Average Target -0,87%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Peter M. Hecht Chief Executive Officer & Director
Terrance G. McGuire Chairman
Thomas Graney Chief Financial Officer & SVP-Corporate Strategy
Mark G. Currie Chief Scientific Officer & Senior Vice President
Brian M. Cali Senior VP-Preclinical, Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IRONWOOD PHARMACEUTICA..34.64%2 268
INCYTE CORPORATION-5.68%19 219
QUINTILES IMS HOLDINGS..11.90%18 225
CELLTRION, INC.--.--%9 953
SEATTLE GENETICS, INC.44.41%9 442
LONZA GROUP AG11.34%9 247
More Results